Search results
Results from the Tech24 Deals Content Network
Exact Sciences Corp. is a molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown ...
Exact Sciences' stool test Cologuard had a 92.3% sensitivity rate. Colorectal cancer occurs in about 150,000 patients in the U.S. annually and is the second-leading cause of cancer fatalities in ...
Top-Line Data Show Exact Sciences' Cologuard Test Demonstrates 92 Percent Sensitivity in the Detection of Colorectal Cancer All endpoints achieved in 10,000-patient trial of non-invasive ...
Guardant's application for Shield was based on a study that showed the test detected 83% of colorectal cancers, while Exact's Cologuard had 92.3% sensitivity rate, according to the FDA's documents.
You are free: to share – to copy, distribute and transmit the work; to remix – to adapt the work; Under the following conditions: attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made.
Exact Sciences (EXAS) reaches a co-promotion agreement with Pfizer to commercialize its non-invasive screening test for colorectal cancer, Cologuard. The stock rallies following this news.
Under “Products,” we would like to add Cologuard before “a non-invasive, Multitarget stool DNA screening test. Cologuard is Exact Sciences best known product and may have equity with those seeking information about the company.” For “Number of employees,” Exact Sciences’ team has grown to ~1,000. Upfront
For premium support please call: 800-290-4726 more ways to reach us